<DOC>
	<DOCNO>NCT00468182</DOCNO>
	<brief_summary>The purpose study determine whether interferon-beta impairs ability plasmacytoid dendritic cell promote pathogenic immune response patient multiple sclerosis .</brief_summary>
	<brief_title>Modulation Plasmacytoid Dendritic Cell Function Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Males female , 18 60 year old , inclusive . Diagnosis relapse form multiple sclerosis determine revise McDonald Criteria least one clinical demyelinate episode abnormal brain MRI study base CHAMPS criterion Expanded disability status scale ( EDSS ) score less 6 entry . Understand sign write informed consent prior test protocol , include screen test evaluation consider part subject 's routine care . Treatment corticosteroid within one month prior study . Treatment immunomodulatory drug within last 3 month prior study . No history treatment Interferonbeta ( IFNbeta ) base drug exclude possibility IFNbeta neutralize antibody Any patient pregnant , intend become pregnant , breastfeeding time study . History significant cardiac , gastrointestinal , hepatic , pulmonary , renal disease ; immune deficiency ; medical condition would preclude IFNbeta therapy . Primary Progressive Multiple Sclerosis patient patient Secondary Progressive Multiple Sclerosis lack recent clinical relapse 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Interferon beta</keyword>
	<keyword>plasmacytoid dendritic cell</keyword>
</DOC>